all report title image
  • Published On : Feb 2022
  • Code : CMI4939
  • Industry : Pharmaceutical
  • Pages : 198
  • Formats :

IVF is a type of assisted reproduction technology in which a woman's reproductive system is artificially encouraged to create oocytes, which are then harvested, fertilized in a lab, and placed in the uterus. Due to complications, IVF specialist provide drugs and food supplements to patients undergoing IVF treatment. IVF treatment procedure includes ovarian stimulation, ovulation induction, oocyte harvest, sperm fertilization, and transport of the fertilized oocytes for implantation. There are various drugs which are commonly used for IVF treatment such as Clomiphene used for inducing ovulation and also injectables available for IVF treatment which includes gonadotropin-releasing hormone (GnRH) and follicle-stimulating hormone (FSH), that produce progesterone to maintain the pregnancy. GonGnRH antagonist inhibit of a premature LH rise and also there are various food supplements which are commonly provided to the patients under IVF treatment such as Coenzyme Q10 (CoQ10) to improve egg quality, sperm quality, and pregnancy rates and DHEA used as an adjuvant for in vitro fertilization (IVF) cycles in poor ovarian responders.

The UAE IVF drugs and food supplements market is estimated to be valued at US$ 20.4 million in 2022, and is expected to exhibit a CAGR of 6.6% during the forecast period (2022-2030).

Figure 1. UAE IVF Drugs and Food Supplements Market Share in Terms of Value (US$ Mn), By Product Type, 2021

UAE IVF Drugs and Food Supplements  | Coherent Market Insights

Favourable initiatives by regulatory authorities for IVF in the country are likely to propel the market growth over the forecast period.

Government initiative for IVF treatment development is expected to drive the UAE IVF drugs and food supplements market over the forecast period in the country. For instance, on October 19, 2019, the President of the United Arab Emirates (UAE), announced the new IVF law. The new IVF law officially came into force from January 1, 2020, repealing the old IVF law. The executive regulations which sit alongside the new IVF law were published in the Official Federal Gazette which includes the laws such as fertility centers are now permitted to freeze human embryos for a period of five years (extendable upon request). Under the new IVF law, subject to compliance with certain controls and procedures, samples of frozen unfertilized or fertilized eggs or sperm may be taken abroad, if prepared in the UAE, or brought into the UAE, if prepared abroad. The new IVF law makes provision for the establishment of a national advisory committee that submits recommendations and proposals in relation to medically assisted reproduction and coordinates between the relevant regulatory authorities in the UAE.

CMI table icon

UAE IVF Drugs and Food Supplements Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022:

US$ 20.4 Mn

Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 6.6% 2030 Value Projection:

US$ 33.9 Mn

Geographies covered:
  • UAE
Segments covered:
  • By Product Type: Drugs (Clomiphene, Injectable Hormones (Human chorionic gonadotropin (hCG), Follicle-stimulating hormone (FSH), Human menopausal gonadotropin (hMG), Gonadotropin-releasing hormone (GnRH), GnRH agonist, GonGnRH antagonist), Food Supplements)
  • By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Shinelife, Adorefem, LG Chem, Adorshea, Biofield Pharma, Medibyte, Mestra Pharma, Dr. D Pharma, Abbott, Zydus, Takeda Pharmaceutical Company Limited, Merck KGaA, and Ferring B.V.

Growth Drivers:
  • Favorable initiatives by regulatory authorities for IVF
  • Increasing inorganic activities among market players 
Restraints & Challenges:
  • High cost of treatment

Figure 2. UAE IVF Drugs and Food Supplements Market Share (%), By Distribution Channel, 2021

UAE IVF Drugs and Food Supplements  | Coherent Market Insights

Market players are indulged in inorganic activities such as partnership, acquisition, and collaboration, which is expected to drive the market growth during the forecast period.

Market players are indulged in inorganic activities such as partnership, acquisition and collaboration, which is expected to propel growth of the UAE IVF drugs and food supplements market during the forecast period. For instance, on March 29, 2019, Boston IVF, an infertility treatment service provider and Ohio Reproductive Medicine, an infertility center, announced new partnership. Moreover, the aim of this partnership is to advance the Ohio Reproductive Medicine’s mission to deliver world-class fertility treatments and care, including in vitro fertilization (IVF), genetic testing, male factor, LGBTQ+ family building, egg freezing, and others. With technology and research playing an increasingly critical role in the quality of patient care, future initiatives will include opportunities for ORM to benefit from Boston IVF’s innovative science that improves IVF outcomes and lessens time in treatment at global level which is expected to cover the UAE IVF drugs and food supplements market owing to the research and development for fertility issues in upcoming years.

UAE IVF Drugs and Food Supplements Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to hamper growth of the UAE IVF drugs and food supplements market during the forecast period. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 340 million cases and 5,570,163 deaths due to coronavirus disease (COVID-19) were reported up till January 23, 2022, across the global.

Furthermore, many hospitals maximize wellbeing of patients, staff, and society at large. There is a confusing picture of the effect of COVID-19 on fertility treatments, with the advice and guidance coming from several different resources such as ASRM (American Society of Reproductive Medicine) stated that in year 2020 some women have postponed their IVF consultations, whereas others have delayed their dates of embryo transfer until the pandemic situation ends and life comes back to normal. According to The U.S.-U.A.E. Business Council In the midst of this public health crisis, the healthcare landscape in the U.A.E. has changed in significant ways, as new key entities launching and consolidating. Abu Dhabi Developmental Holding Company (ADQ), an investment management company that had a broad portfolio of important healthcare enterprises in Abu Dhabi such as Abu Dhabi Health Services Company (SEHA), continued its expansion into the healthcare space by launching Union 71, a laboratory testing company, and Rafed, a Group Purchasing Organization to manage and develop the procurement of healthcare-related services and products after the emergence of these two groups, ADQ signed an agreement merging both Rafed and Union71 with Pure Health, a key integrated healthcare solutions provider in the U.A.E.

UAE IVF Drugs and Food Supplements Market: Restraint

The higher cost of treatment as compared to other countries in the UAE is considered the major limiting factor for more patients coming from abroad. However, based on Colliers’s discussions with major providers in the UAE which states that the high success rates and quality are directly related to the significant investments made in this sector both in equipment and staff. If treatment fees for IVF are substantially reduced, it will have an impact on the UAE’s ability to retain the IVF facilities.

Key Players

Major players operating in the UAE IVF drugs and food supplements market include Shinelife, Adorefem, LG Chem, Adorshea, Biofield Pharma, Medibyte, Mestra Pharma, Dr. D Pharma, Abbott, Zydus, Takeda Pharmaceutical Company Limited, Merck KGaA, and Ferring B.V.

In vitro fertilization (IVF) is a form of assisted reproductive technology in which a woman’s reproductive system is artificially stimulated to produce oocytes, which are extracted, fertilized in a laboratory, and then implanted in the uterus. This is a multistep process that needs to be carefully controlled with the use of medications due to the complex interplay of the various drugs used to replicate the different stages of the fertilization process by IVF healthcare team. IVF is a multistep process involving ovarian stimulation, ovulation induction, collection of oocytes, fertilization with sperm, and transfer of the fertilized oocytes to the uterus for implantation and maturation by following various stages. At each stage, there are different protocols for the use of these drugs, and the most appropriate pharmacologic regimen and therapeutic intervention are chosen after a thorough pre-treatment evaluation and an accurate diagnosis, controlled ovarian stimulation is achieved with the use of gonadotropin-releasing hormone (GnRH) analogues and inhibitors of natural steroid hormones, such as clomiphene citrate, recombinant follicle-stimulating hormone (FSH), and luteinizing hormone (LH) and also by providing food supplements to patients, such as Coenzyme Q10 (CoQ10) and DHEA are two supplements that are often used to help older women (over 35) and those with limited ovarian reserve. These are commonly used by women who are undergoing IVF to boost the number of eggs generated by their ovaries.

Market Dynamics

Key players and market players operating in the market are focusing on expanding and developing efficient IVF facilities which can be attributed to the growth of the UAE IVF drugs and food supplements market. For instance, on November 14, 2021, Mediclinic Middle East, which is a part of Mediclinic International and hospital group that operates seven hospitals in the UAE announced the 100% acquisition of Bourn Hall Fertility Centre, an IVF specialties center in the MENA region from TVM Capital Healthcare, following an initial acquisition of 30% of the shares in December 2018.The aim of this acquisition is to provide the highest level of quality care with exceptional outcomes through this acquisition to provide better services for IVF facilities.

Key features of the study:

  • This report provides an in-depth analysis of the UAE IVF drugs and food supplements, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the UAE IVF drugs and food supplements based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
  • Key companies covered as a part of this study include Shinelife, Adorefem, LG Chem, Adorshea, Biofield Pharma, Medibyte, Mestra Pharma, Dr. D Pharma, Abbott, Zydus, Takeda Pharmaceutical Company Limited, Merck KGaA, and Ferring B.V.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The UAE IVF drugs and food supplements report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the UAE IVF drugs and food supplements market.

Detailed Segmentation:

  • UAE IVF Drugs and Food Supplements Market, by Product Type:
    • Drugs
      • Clomiphene
      • Injectable Hormones
        • Human chorionic gonadotropin (hCG)
        • Follicle-stimulating hormone (FSH)
        • Human menopausal gonadotropin (hMG)
        • Gonadotropin-releasing hormone (GnRH)
        • GnRH agonist
        • GonGnRH antagonist
    •  Food Supplements
  • UAE IVF Drugs and Food Supplements Market, by Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • Shinelife*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Adorefem
    • LG Chem
    • Adorshea
    • Biofield Pharma
    • Medibyte
    • Mestra Pharma
    • D Pharma
    • Abbott
    • Zydus
    • Takeda Pharmaceutical Company Limited
    • Merck KGaA
    • Ferring B.V.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The UAE IVF drugs and food supplements market is estimated to be valued at US$ 20.4 million in 2022, and is expected to exhibit a CAGR of 6.6% between 2022 and 2030.
Factors such as increased research and development activities in market, and inorganic activities among market players are expected to drive the market growth during the forecast period.
Drugs segment is expected to hold a major market share during the forecast period in the product type segment.
The major factor hampering growth of the market include stringent government regulations and high cost of products and procedures.
Major players operating in the market include Shinelife, Adorefem, LG Chem, Adorshea, Biofield Pharma, Medibyte, Mestra Pharma, Dr. D Pharma, Abbott, Zydus, Takeda Pharmaceutical Company Limited, Merck KGaA, and Ferring B.V.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo